Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.

Study Overview
=================
Brief Summary
-----------------
Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.

Detailed Description
-----------------
Studies have already demonstrated the feasibility of prognostic role of protein biomarkers change during the treatment trajectory of patients in several carcinoma,However, no study focused on the value of trajectory analysis of blood cells counts of Immunochemotherapy in patients with advanced esophageal cancer. The investigators plan to analyze the dynamic change of blood cells counts longitudinally from preoperation to long term follow-up in advanced esophageal cancer and predict the efficacy and safety of immunochemotherapy.

Official Title
-----------------
Trajectory Analysis of Neutrophil to Lymphocyte Ratio（NLR） and Its Association With Efficacy of Immunochemotherapy in Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study

Conditions
-----------------
Esophageal Squamous Cell Carcinoma, Immunotherapy, Chemotherapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed esophageal squamous cell carcinoma Potentially resectable esophageal squamous cell carcinoma at first diagnosis (cT1-4a N1-2 M0, cT3-T4a N0M0) Treatment-naive Expected life span > 6 months Aged 18 - 75 years old Adequate organ functions Performance Status (PS) 0-2 Participants are fully informed about the whole study and are willing to sign the informed consent Exclusion Criteria: Previous history of thoracic surgery or radiation Cervical or multi-origin esophageal cancer Known or suspected experimental drug allergy Pregnant or lactating women Esophagomediastinal fistula Peripheral neuropathy Previous cancer history other than esophageal cancer Severe organ function deterioration that can not tolerate neoadjuvant therapy Previous autoimmune diseases diabetic history > 10 years interstitial pulmonary disease, non-infectious pulmonitis Active type B hepatitis Any other conditions that may affect patients' safety and compliance
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival and disease-free survival. | Overall survival rate | From the date of diagnosis to the date of death, assessed up to 100 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathologic complete response rate | The rate of pathologic complete response rate after the combined treatment of chemotherapy and immunotherapy following surgery | Three to five working days after surgery | 
| Objective Response Rate (ORR) | Immune-modified Response Evaluation Criteria In SolidTumors (iRECIST) criteria defined complete response and partial response | Up to 24 weeks | 
| Major pathological response | ess than 10% residual viable tumor follow neoadjuvant therapy | Three to five working days after surgery | 
| Event-free survival | Event-free survival (EFS) | From the date of treatment initiation to the date of first progression (local recurrence of tumor or distant metastasis) or death from any cause, assessed up to 100 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced Esophageal Carcinoma, Immunochemotherapy, Trajectory analysis, Blood cell counts